This measure assesses the percentage of members 18–64 years of age with schizophrenia or schizoaffective disorder and diabetes, who had both an LDL-C test and an HbA1c test during the measurement year.
Why It Matters
An estimated 33.4% of people with schizophrenia have metabolic syndrome—a rate nearly two times higher than that of the general population.1
Among patients with co-occurring schizophrenia and metabolic disorders, the nontreatment rate for diabetes is approximately 30%.2 In addition to general diabetes risk factors, diabetes is promoted in patients with schizophrenia by initial and current treatment with olanzapine and mid-potency first-generation antipsychotics (FGA), as well as by current treatment with low-potency FGAs and clozapine.3
Historical Results – National Averages
Get Access to the Historical Results
By completing the form below, you’ll gain free access to national performance data.
"*" indicates required fields
References
- Murphy, S.L., J.Q. Xu, J.D. Kochanek. March 1, 2013. “Deaths: final data for 2010.” Morbidity and Mortality Weekly Report (MMWR). 62(08);155 https://www.cdc.gov/nchs/data/nvsr/nvsr61/nvsr61_06.pdf
- Save
Save your favorite pages and receive notifications whenever they’re updated.
You will be prompted to log in to your NCQA account.
Save your favorite pages and receive notifications whenever they’re updated.
You will be prompted to log in to your NCQA account.
- Email
Share this page with a friend or colleague by Email.
We do not share your information with third parties.
Share this page with a friend or colleague by Email.
We do not share your information with third parties.
- Print
Print this page.
Print this page.